Politics

South Dakota House Blunts GW Pharma Bill

Published on March 2, 2017 · Last updated July 28, 2020
South Dakota state capitol building in Pierre, SD.

A South Dakota House committee has amended a controversial cannabidiol (CBD) bill to exclude language that would have given the pharmaceutical company GW Pharma a temporary de facto monopoly of the state’s CBD market.

Senate Bill 95 passed the South Dakota Senate last month. It gained notoriety as one of two bills backed by GW Pharma and its American subsidiary, Greenwich BioSciences, that would move CBD to Schedule IV on state drug regimes—but only CBD in a form that’s received FDA approval. GW/Greenwich’s drug Epidiolex, which treats intractable epilepsy, is expected to received FDA approval as soon as this summer. There is no other FDA-approved CBD drug on the market.

Leafly News broke the story of the GW/Greenwich bills last month. A GW spokesperson has stated that the company is not attempting to create a monopoly; it just wants patients to be able to access Epidiolex if and when the drug receives FDA clearance.

GW/Greenwich officials have been lobbying South Dakota legislators this past week, as have a number of medical cannabis patients and patient advocates. George Hendrickson, an outspoken advocate whose young son struggles with Dravet syndrome, spoke in favor of amending the bill, as did Teri Robnett, a medical marijuana patient and advocate from Colorado, and Melissa Mentele, chairperson of New Approach South Dakota.

At the end of the SB 95 hearing, members of the House committee voted to remove language that defined cannabidiol as “a drug approved by the United States Food and Drug Administration.”

The bill as it now stands would remove CBD from the state’s definition of marijuana, and define it as a Schedule IV drug within South Dakota’s classification system. That would mean all forms of CBD, not just those that have been approved by the FDA, would be considered Schedule IV substances.

If the bill receives full House approval, it would then have to be re-approved by the Senate in its amended form.

Shop highly rated stores near you

Showing you stores near
See all stores
Bruce Barcott
Bruce Barcott
Leafly Senior Editor Bruce Barcott oversees news, investigations, and feature projects. He is a Guggenheim Fellow and author of Weed the People: The Future of Legal Marijuana in America.
View Bruce Barcott's articles
Get good reads, local deals, and strain spotlights delivered right to your inbox.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.



Stay In Touch

Receive updates on new products, special offers, and industry news.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.

Leafly mobile app
Get high for less.
Download the Leafly app.
Download Leafly: Marijuana Reviews on the App Store
Download Leafly Marijuana Reviews on Google Play




The material provided on Leafly is intended for educational and informational purposes only. Leafly is not engaged in rendering medical service or advice and the information provided is not a substitute for a professional medical opinion. If you have a medical problem, please contact a qualified health professional.


© 2024 Leafly, LLC
Leafly and the Leafly logo are registered trademarks of Leafly, LLC. All Rights Reserved.